Oncolytics Biotech (ONCY) Invested Capital (2018 - 2026)

Oncolytics Biotech (ONCY) has reported Invested Capital for 9 consecutive years, with -$6.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Invested Capital fell 220.13% year-over-year to -$6.2 million in Q2 2026; TTM through Jun 2026 was -$6.2 million, a 220.13% decrease from a year earlier, with the FY2025 full-year figure at -$3.7 million, down 173.18% from the prior year.
• Invested Capital was -$6.2 million for Q2 2026 at Oncolytics Biotech, down from -$3.7 million in the prior quarter.
• Over five years, Invested Capital peaked at $27.7 million in Q1 2022 and troughed at -$6.2 million in Q2 2026.
• A 5-year average of $12.9 million and a median of $16.7 million in 2023 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital gained 17.02% in 2023 and tumbled 220.13% in 2026, its largest moves.
• Over 5 years, Invested Capital stood at $19.6 million in 2022, then climbed by 3.39% to $20.2 million in 2023, then tumbled by 75.38% to $5.0 million in 2024, then plunged by 174.67% to -$3.7 million in 2025, then plunged by 65.69% to -$6.2 million in 2026.
• The last three Invested Capital figures came in at -$6.2 million (Q2 2026), -$3.7 million (Q4 2025), and $104635.4 (Q3 2025), per Business Quant data.